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A B S T R A C T
Objectives: Thymosin alpha1 (Ta1) is considered a promising immunomodulatory drug. However, it is
still unclear whether Ta1 should be recommended for the management of sepsis. Here we conducted a
systematic review and meta-analysis to assess the efﬁcacy of Ta1 based immunomodulatory therapy on
the clinical outcomes of septic patients.
Methods: We searched for relevant clinical trials published before Dec. 12, 2014 through electronic
databases. All articles about Ta1 based immunomodulatory therapy for sepsis were included regardless
of language. Two authors independently selected studies, extracted data and assessed the quality of each
included study. We polled the data related to all-cause mortality with Review Manager 5.1.
Results: Twelve controlled trials were evaluated in all. Ta1 based immunomodulatory therapy had a
signiﬁcant trend toward lower all-cause mortality among patients with sepsis (pooled risk ratio 0.68,
95%CI 0.59-0.78, p < 0.00001, 12 trials, n = 1480).
Conclusions: Ta1 based immunomodulatory therapy was associated with a lower mortality in septic
patients. Nevertheless, these ﬁndings should be interpreted cautiously because of the poor quality and
small number of participants of the included trials. More well-designed worldwide multicenter clinical
trials are needed to provide a conclusive guideline for clinical practice.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Severe sepsis remains one of the major causes of mortality
among critically ill patients, even under modern critical care
management, and it also leads to heavy economic burden
worldwide1–3. It affects more than 751,000 patients just in the
United States per year1, with a mortality ranges from 20% to
45.8%4–6. It is well known that sepsis is a syndrome characterized
by systemic inﬂammation resulting from severe infection,
followed by acute multiple-organ failure, and even death7–9. Early
appropriate use of antibiotics, aggressive source control and
hemodynamic management were related to improved outcomes in
terms of mortality in severely septic patients
9–11
. However, there
are still no speciﬁc drugs or treatment strategies for this serious
disorder. Although there were several promising drugs under
investigating for the treatment of sepsis, such as drotrecogin alfa* Corresponding author. Tel.:/fax: +86-029-84777425.
E-mail addresses: licong1988@hotmail.com (C. Li), boliyan@hotmail.com (L. Bo),
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1 These authors contributed to the article equally.
http://dx.doi.org/10.1016/j.ijid.2014.12.032
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).(human recombinant activated protein C)12, eritoran (Toll-like
receptor 4 blocker)13, and talactoferrin (human recombinant
lactoferrin)14, none of them achieved a satisfactory result because
of failure to conﬁrm the efﬁcacy12, unsuccessfully getting
efﬁcacious endpoint13 and toxic effects14, respectively. For these
reasons, it is urgent to ﬁnd new directions for sepsis studies14–18.
Two studies conducted by Limaye et al.19 and Luyt et al.20 shed
light on this challenge. They uncovered an underlying mechanism
of this critical illness by proving the concept that the critical illness
can induce immunosuppression. Since they found that most septic
patients admitted to intensive care units had septic foci21, growing
evidence has indicated that early sepsis is characterized by
hyperinﬂammatory symptoms, such as fever, altered mental status
and organ dysfunction22. As sepsis persists, immune depression
occurs, which is mediated by mechanisms including depletion of
CD4+ T, CD8+ T, B, and dendritic cells as well as decreasing
production of both proinﬂammatory and antiinﬂammatory cyto-
kines23–29. Therefore, as discussed by Richard Hotchkiss30, sepsis
could be considered to be a complex immune disorder with both a
hyperinﬂammatory stage and subsequently a hypoinﬂammatory
stage31. So severely septic patients might beneﬁt from therapies
that reinforce host immunity23,24,32.ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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peptide33, is widely used in clinical trials for the treatment of
immunodeﬁciency related diseases34–36. It has been proven
efﬁcient in the treatment of chronic B and C hepatitis as well
as some types of cancers34–37. It has also been extensively
described as the immunomodulatory activity on innate immune
cells, such as polymorphonuclear leucocytes, dendritic cells, and
macrophages38. Adaptive T helper immunity was also reported as
being able to be affected by Ta139. The results of animal
experiments signiﬁcantly implied that Ta1 can help mice survive
sepsis40, whereas the clinical trials regarding the effect of Ta1
based immunomodulatory therapy on mortality of severely septic
patients did not achieve a consistent conclusion.
In order to unequivocally ascertain the role of Ta1 on sepsis,
many efforts have been made. A systematic review conducted by
Yu et al.41 concluded that Ta1 could ameliorate immunosuppres-
sion caused by severe sepsis. However, a signiﬁcant improvement
in mortality was not observed. After that, some trials with more
participants were reported. Therefore we performed this review of
the controlled trials involving Ta1 based immunomodulatory
therapies in septic patients to assist practitioners and researchers
appropriately in determining the efﬁcacy of this strategy and
guiding further research in this area.
2. Methods
The literature search, study selection, data extracted and
assessment of risk of bias were performed independently by two
authors (CC Li and LY Bo) using the standard strategy mentioned
below. All discrepancies were ﬁrstly discussed and resolved by
consensus, and the senior reviewer (Jin FG) was consulted for the
ﬁnal decision if consensuses were not reached.
2.1. Search strategy
We performed a computer-aided literature search using
databases including EMBASE, MEDLINE (PubMed), Cochrane
Central Register of Controlled Trials in English and China National
Knowledge Infrastructure (CBM), VIP Database for Chinese
Technical Periodicals (VIP) in Chinese to retrieve potentially
relevant controlled trials. We mainly used the following search
terms: Thymosin alpha1, Thymosin, Thymus, Maipuxin, Thymal-
fasin, and Zadaxin. All articles and conference abstracts about Ta1
based immunomodulatory therapies for sepsis were identiﬁed
regardless of language.
2.2. Study selection
Studies were included if they met all of the following criteria:
(1) Participants: patients had to be diagnosed with sepsis. (2) Type
of studies: studies were eligible only if they were controlled
clinical trials. (3) Type of interventions: studies used Ta1 based
immunomodulatory therapies. Studies were excluded if they did
not provide outcomes related to mortality or were duplicated
publications.
2.3. End points and data extraction
The primary end point was all-cause mortality, and the second
end point was adverse events. For all-cause mortality, we used 28-
day mortality. If 28-day mortality could not be acquired, we used
ICU or hospital mortality instead. We also extracted and collected
the relevant information about each study, such as characteristics
of studies, characteristics of participants, immunomodulatory
therapy strategies and types of outcomes.2.4. Quality assessment
We evaluated the quality of the included trials independently
by two authors (CC Li and LY Bo). The methodological qualities of
included controlled trials were evaluated using a modiﬁed Jadad
Scale42. The full score is 7, with 4-7 being regarded as high quality
and 1-3 as low quality. We also assessed the risk of bias using the
domain-based evaluation that includes: selection bias, perfor-
mance bias, detection bias, attrition bias, reporting bias and other
bias43.
2.5. Data processing and statistical analysis
Treatment effects on total mortality were pooled to obtain
estimates of summary effect. For dichotomous outcomes, we
calculated relative risk (RR) and 95% conﬁdence interval (CI) of
every study and estimated the overall Mantel-Haenszel (M-H) RR
as well as the 95% CI. I2 statistic and Chi2 test were used to examine
the heterogeneity, and if signiﬁcant heterogeneity (p0.10 for Chi2
test results or I250%) was obtained we used a random-effects
model, and otherwise a ﬁxed-effects model was used. Subgroup
analyses were performed according to the immunomodulatory
therapy strategy, type of blind, outcome measures and Ta1 dose.
Sensitivity analyses were performed by excluding every single
study or subgroup, re-analyzing and comparing with the original
RR to test the robustness of our results. In addition we reanalyzed
the data by excluding the low quality studies and only pooling the
data from high quality studies (modiﬁed Jadad Score 4). To
evaluate publication bias, we constructed a funnel plot and
calculated a classic fail-safe number to estimate the number of
missing studies that needed to yield a statistically non-signiﬁcant
overall effect. Hypothesis testing was considered statistically
signiﬁcant if two-side p-value0.05. Data synthesis and subgroup
analyses were done using Review Manager (version 5.1), and
classic fail-safe N was estimated using Comprehensive Meta
Analysis (V2).
3. Results
We identiﬁed 465 potentially relevant articles in the initial
search, and twelve studies (N = 1480 patients)44–55 satisﬁed the
inclusion criteria. All of them were included in the meta-analysis
(Figure 1). The key characteristics of included trials were
summarized in Additional ﬁle 1. When stratiﬁed by types of
immunomodulation therapy strategies, 6 studies were treated
with thymosin alpha1 and 6 studies with thymosin alpha1+uli-
nastain (Ta1+UTI). Stratiﬁed by outcome measures, 10 studies
reported 28-day mortality and 2 studies reported ICU mortality.
Stratiﬁed by Ta1 doses, 8 studies used high dose Ta1 (>1.6 mg/
day) and 4 studies used low dose Ta1 (1.6 mg/day). The mean age
of the participants ranged from 43.5 to 67.37. The mortality rate of
control groups ranged from 33.33% to 65.45%.
When assessing the quality of the included studies, we found
7 studies were rated as high quality according to the modiﬁed
Jadad Scale. As presented in Additional ﬁle 2: Table S2, most of the
included studies were of high risk or unclear in reporting random
sequence generation as well as allocation concealment. Blinding of
participants and personnel was adequate only in three studies. All
studies were of low risk for detection bias and attrition bias. The
results about the quality of the studies indicated that the ﬁnal
results of this meta-analysis may be potentially not robust, and
need further subgroup and sensitivity analysis.
Overall, as shown in Figure 2, the effect of Ta1 based
immunomodulatory therapy on all-cause mortality was statisti-
cally signiﬁcant (M-H RR, 0.68 [95%CI, 0.59-0.78]; p < 0.00001).
Overall mortality of 12 studies was 35.27% and the mortality in the
Figure 1. PRISMA Flow Diagram.
Figure 2. Forest plot of the association between tested treatments and mortality among patients with severe sepsis.
C. Li et al. / International Journal of Infectious Diseases 33 (2015) 90–9692
Table 1
Subgroup analyses by types of interventions, Thymosin alpha1 doses, outcome measures and types of blind.
No. of Studies No. of Patients Risk Ratio 95%CI Heterogeneity (I2) Test for Effect (p)
Type of intervention
Ta1 6 565 0.68 (0.53,0.87) 0% 0.002
Ta1+UTI 6 915 0.67 (0.57,0.80) 0% <0.00001
Ta1Dose
High dose 8 1265 0.66 (0.57,0.77) 0% <0.00001
Low dose 4 276 0.74 (0.55,1.01) 0% 0.05
Outcome measure
28-day mortality 10 1404 0.67 (0.58,0.78) 0% <0.00001
ICU mortality 2 76 0.73 (0.40,1.31) 0% 0.29
Type of blind
Double-blind 1 56 0.55 (0.23,1.33) NA 0.19
Single-blind 4 589 0.68 (0.55,0.83) 0% 0.0002
No-blind 7 835 0.68 (0.56,0.83) 0% <0.0001
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groups. No signiﬁcant heterogeneity was found across the
12 studies (x2 = 6.25, df = 11 (p = 0.86); I2 = 0%).
To explore the relationships between different immunomodu-
latory therapy strategies and mortality, we conducted the
subgroup analyses, and found that both Ta1 (M-H RR, 0.68 [95%
CI, 0.53-0.87]; p = 0.002; 6 trials, n = 565; heterogeneity, p = 0.67)
and Ta1+UTI (RR, 0.67 [95% CI, 0.57-0.80]; p < 0.00001; 6 trials,
n = 915; heterogeneity, p = 0.69) could decrease the mortality of
severely septic patients (see Figure 3). We also performed
subgroup analyses by stratifying previous analysis according to
factors that might inﬂuence the outcomes of clinical trials, such as
Ta1 doses, outcome measures and blind strategies (Table 1). The
analyses revealed that only the high dose Ta1 (M-H RR, 0.66 [95%Figure 3. Forest plot of the association between tested treatments and mCI, 0.57-0.77]; p < 0.00001; 8 trials, n = 1265; heterogeneity,
p = 0.89) could signiﬁcantly decrease all-cause mortality. Howev-
er, the low dose Ta1 (M-H RR, 0.74 [95% CI, 0.55-1.01]; p = 0.05;
4 trials, n = 215; heterogeneity, p = 0.47) did not achieve a similar
result. Also, there was no obvious subgroup difference (x2 = 0.46,
df = 1 (p = 0.50); I2 = 0%) (see Additional ﬁle 3: Figure S1). When
stratiﬁed by outcome measures, the subgroup-speciﬁc pooled M-H
RR was 0.67 (95% CI, 0.58, 0.78) for 28-day mortality, and 0.73 (95%
CI, 0.40, 1.31) for ICU mortality (see Additional ﬁle 3: Figure S2).
When stratiﬁed by blind strategies, the subgroup-speciﬁc pooled
M-H RR was 0.55(95% CI, 0.23, 1.33) for double-bind studies, 0.68
(95% CI, 0.55, 0.83) for single-blind studies, and 0.68 (95% CI, 0.56,
0.83) for no-blind studies, respectively (see Additional ﬁle 3:
Figure S3).ortality among patients with severe sepsis, by types of interventions.
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single study or subgroup, re-analyzing and comparing with the
original H-M RR to test the robustness of our results. None of these
alterations affected the ﬁnal results. We also conducted a
sensitivity analysis restricted to studies of high quality, and the
result (M-H RR, 0.69 [95% CI, 0.59-0.81]; p < 0.00001; 7 trials,
n = 1078; heterogeneity, p = 0.74) was consistent with that
obtained by pooling all available studies (see Additional ﬁle 3:
Figure S4).
Two studies44,55 reported that no Ta1-related adverse effects
occurred. Also no treatment was discontinued because of
intolerance. The other studies did not mention adverse effects.
No evidence of publication bias was detected by funnel plots
(Figure 4). Classic fail-safe N was 81, indicating that no less than
81 missing studies would be needed to bring the p-value to >0.05
and yield a statistically not signiﬁcant overall effect.
4. Discussion
In this meta-analysis, we performed a comprehensive literature
search without language limitation, and found that Ta1 based
immunomodulatory therapy was signiﬁcantly associated with a
decrease in all-cause mortality among patients with sepsis by
systematically analyzing all 12 relevant studies. Overall, subcuta-
neous injection of Ta1 alone or combined with ulinastain could
signiﬁcantly improve mortality of septic patients through modu-
lating the immune system. However, because of the poor quality of
some included trials, these ﬁndings should be applied cautiously.
It was believed that severe sepsis led to death by exaggerated
pro-inﬂammatory response and inﬂammation-induced organ
failures, previously. Many drugs were designed and tested based
on this theory. Frustratingly, over 25 trials of new agents
failed23,30. This condition was more or less due to the misunder-
standing of the pathophysiologic mechanisms about the develop-
ment of sepsis. More than simply elevating immunologic response,
sepsis initiates complex systemic inﬂammatory reactions com-
posed of two stages: the pro-inﬂammatory responses dominated
the ﬁrst stage and the anti-inﬂammatory responses dominated the
second stage22,24,32. A majority of septic patients can survive the
hyperinﬂammatory phase with modern standard-of-care mea-
sures and enter into an immunosuppressive stage characterized by
depleting cells of both the innate and adaptive immune system,
failure to eradicate the primary infection, and occurrence of fatal
secondary infections24. So the fundamental problem in septic
patients is loss of immune competence. From this perspective,
patients may beneﬁt from drugs that can enhance immune
competence and eventually eliminate the immunosuppressiveFigure 4. Funnel plot of the standard error by log relative risk of all-cause mortality.condition. Some immune-enhancing agents, such as granulocyte
macrophage colony stimulating factor (GM-CSF)56, interleukin
757,58 and antibody target PD-1 or its ligand (PD-L1)59–61, were
under investigation and have shown potential for the treatment of
sepsis. Ta1 has shown similar immune-enhanced effects, both in
animals and in clinical studies38. It has been reported that it could
enhance NK cell activity and induce the differentiation and
maturation of T cells38. A systematic review conducted by Yu
et al.,41 showed that Ta1 could restore the ‘‘exhausted’’ T cells, but
did not yield a signiﬁcant improvement of mortality.
In our review, we achieved a positive conclusion through
including some other relevant and newly reported trials. However,
there are still issues that need further exploration. There were two
kinds of Ta1 based immunomodulatory therapy strategies that
were effective based on our study, and their efﬁciency was similar
(Ta1 RR vs. Ta1+UTI RR; 0.68 vs. 0.67). To select the most optimal
scheme, additional work is needed. A similar problem was
encountered when the impact of different doses on mortality
was analyzed. According to our ﬁndings, there was no signiﬁcant
difference in mortality between high dose subgroup and low dose
subgroup. This conclusion is contrary to the opinion of CGITS54. The
discrepancies of patients’ conditions may be one of the possible
reasons. This may also be because both our conclusion and the
opinions of CGITS were based on results from between-study
rather than within-study contrast. Therefore, we need a well-
designed multi-dose clinical trial to settle this problem. Another
subgroup analysis about outcome measures was performed. It is
noticeable that, unlike 28-day mortality, treatments could not
statistically improve ICU mortality. Aside from the lack of relevant
studies, the immune state of patients and onset time of
immunomodulatory therapy may also play vital roles. As
immunosuppression is the second stage of severe sepsis, only
the patients who survive the early hyperinﬂammatory stage can
enter into this stage several days later. Therefore Ta1, as an
immune stimulate agent, is very likely effective on later sepsis.
There are several limitations of this report that need to be
mentioned. Firstly, all of the included trials were conducted in
China. The discrepancy among races may affect the effect of
therapies and prognosis. Secondly, the studies were small in size
(only 3 trials had more than 100 participants), and poor in quality.
Fortunately, the sensitive analyses proved that the results were
relatively stable. Thirdly, there was variability in the study design
and bias, namely, methodological heterogeneity. Most of these
studies were not double-blind. Also, these trials might underreport
the adverse effects because many of the included studies failed to
mention them. Finally, we did not assess the correlation between
monocyte human leukocyte antigen-DR (mHLA-DR) and mortality
because of an inadequacy of information. As the most frequently
assessed biomarker of immune function in septic patients, mHLA-
DR surface expression is a good predictor of mortality62. The
dynamic change of mHLA-DR is closely associated with prognosis
of severe sepsis62. Therefore, in further trials, the selection of
participants and onset of immunomodulatory therapy should be
based on the quantized immune competence by mHLA-DR and
other biomarkers.
5. Conclusions
Overall, Ta1 based immunomodulatory therapy signiﬁcantly
reduces the risk of all-cause mortality among septic patients.
Subgroup analyses showed that either the use of Ta1 alone or
combination with ulinastain could bring about lower mortality in
patients with sepsis. Nevertheless, these ﬁndings should be
interpreted cautiously because of the poor quality and small
number of participants of the included trials. More well-designed
C. Li et al. / International Journal of Infectious Diseases 33 (2015) 90–96 95worldwide multicenter clinical trials are needed to provide a
conclusive guideline for clinical practice.
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